Menu

The Moores Cancer Center, located on the UC San Diego Health Campus and also known as University of California San Diego Cancer Center, is a National Cancer Institute (NCI) designated Comprehensive Cancer Center. It is the only cancer center to receive the designation in the San Diego area. The center employs 14 cancer teams that work together in specialty and subspecialty groups to treat patients with both common and rarer cancers, like mesothelioma. These multidisciplinary teams treat not only the patient’s cancer, but also provides holistic support for the patient, their family and caregivers. Support services offered include support groups, nutrition services and other emotional support services.

Mesothelioma patients receiving care at the Moores Cancer Center benefit from their Rare Tumor Clinic, which emphasizes genomically targeted treatments with immunotherapy. The center also offers a wide array of clinical trials, which enables patients to receive cutting edge care. The Moores Cancer Center frequently offers over 100 clinical trials at one time, allowing patients easier access to emerging therapies. One such cutting edge therapy offered at the center is heated intraperitoneal chemotherapy or HIPEC, a treatment that has proven to lead to improved survival rates for peritoneal mesothelioma. The surgeons at Moores are some of the most experienced at the cytoreductive/HIPEC surgery combination, performing around three procedures each week.

In addition to HIPEC, the physicians at the Moores Cancer Center are well versed in other procedures commonly used for mesothelioma treatment, including thoracoscopy and the standard treatment modalities: radiation, chemotherapy and general surgery.

Specializations:

  • Chemotherapy
  • Clinical trials
  • Cytoreductive surgery
  • Genomics
  • Heated intraperitoneal chemotherapy (HIPEC)
  • Immunotherapy
  • Mesothelioma
  • Palliative care
  • Peritoneal mesothelioma
  • Personalized cancer therapy
  • Radiation oncology
  • Thoracoscopy

Accreditations:

  • American College of Surgeons Commission on Cancer (CoC) Accreditation
  • Cancer Center ranked as High Performing according to U.S. News & World Report Best Hospitals report
  • Included in the 100 Hospitals and Health Systems with Great Oncology Programs report by Becker’s Hospital Review
  • NCI-designated Comprehensive Cancer Center

Mesothelioma Clinical Trials at University of California San Diego (UCSD) Health

The following clinical trials are in progress or actively recruiting participants at University of California San Diego (UCSD) Health:

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors


Conditions: Carcinoma, Carcinoma, Squamous Cell, Adenocarcinoma, Neoplasms, Germ Cell and Embryonal, Mesothelioma, Breast Neoplasms, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Carcinoma, Basal Cell, Gastrointestinal Stromal Tumors, Carcinoid Tumor, Carcinoma, Transitional Cell, Carcinoma, Adenoid Cystic, Teratoma, Adenocarcinoma of Lung, Carcinoma, Neuroendocrine, Seminoma, Pheochromocytoma, Choriocarcinoma, Cystadenocarcinoma, Cystadenocarcinoma, Serous, Carcinoma, Endometrioid, Chordoma, Paraganglioma, Hemangiosarcoma, Fibromatosis, Aggressive, Trophoblastic Neoplasms, Adenocarcinoma, Mucinous, Gestational Trophoblastic Disease, Adenocarcinoma, Clear Cell, Nerve Sheath Neoplasms, Neurofibrosarcoma, Cystadenocarcinoma, Mucinous, Fibroma, Thyroid Neoplasms, Pseudomyxoma Peritonei, Sex Cord-Gonadal Stromal Tumors, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Vulvar Neoplasms, Paget Disease, Extramammary, Adenocarcinoma, Papillary, Carcinoma, Acinar Cell, Adenocarcinoma, Bronchiolo-Alveolar, Mixed Tumor, Mullerian, Carcinoma, Giant Cell, Neoplasms, Unknown Primary, Neoplasms

Last Updated: September 6, 2019

Status: Recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors


Conditions: Carcinoma, Carcinoma, Squamous Cell, Adenocarcinoma, Neoplasms, Germ Cell and Embryonal, Mesothelioma, Breast Neoplasms, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Carcinoma, Basal Cell, Gastrointestinal Stromal Tumors, Carcinoid Tumor, Carcinoma, Transitional Cell, Carcinoma, Adenoid Cystic, Teratoma, Adenocarcinoma of Lung, Carcinoma, Neuroendocrine, Seminoma, Pheochromocytoma, Choriocarcinoma, Cystadenocarcinoma, Cystadenocarcinoma, Serous, Carcinoma, Endometrioid, Chordoma, Paraganglioma, Hemangiosarcoma, Fibromatosis, Aggressive, Trophoblastic Neoplasms, Adenocarcinoma, Mucinous, Gestational Trophoblastic Disease, Adenocarcinoma, Clear Cell, Nerve Sheath Neoplasms, Neurofibrosarcoma, Cystadenocarcinoma, Mucinous, Fibroma, Thyroid Neoplasms, Pseudomyxoma Peritonei, Sex Cord-Gonadal Stromal Tumors, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Vulvar Neoplasms, Paget Disease, Extramammary, Adenocarcinoma, Papillary, Carcinoma, Acinar Cell, Adenocarcinoma, Bronchiolo-Alveolar, Mixed Tumor, Mullerian, Carcinoma, Giant Cell, Neoplasms, Unknown Primary, Neoplasms

Last Updated: September 6, 2019

Status: Recruiting

A Study of ABBV-181 in Participants With Advanced Solid Tumors


Conditions: Neoplasms

Last Updated: July 26, 2019

Status: Recruiting

Photo of University of California San Diego (UCSD) Health

Get Help Contacting University of California San Diego (UCSD) Health


    Privacy policy: All information is secure and will never be released

    TRUSTe

    Free

    Mesothelioma Treatment Guide

    Please fill in the form to request our FREE Mesothelioma Treatment Guide.
    It will be sent to you within 24 hours.

    Free Mesothelioma Treatment Guide



      Privacy policy: All information is secure and will never be released

      TRUSTe